Trial Profile
A Prospective Randomized Phase II Study to Identify Predictive Biomarkers and Mechanisms of Therapy Resistance in Patients With HER2-negative Metastatic Breast Cancer Treated With the Combination of Bevacizumab and Paclitaxel (BEVPAC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms BEVPAC
- 25 Feb 2019 Status changed from recruiting to completed.
- 16 Aug 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
- 22 Feb 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018 as reported by ClinicalTrials.gov.